Across TCGA pan-cancer cohorts, MT-ATP8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MT-ATP8 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MT-ATP8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MT-ATP8 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where MT-ATP8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.866	0.604	<.001	52	view →
GBM	OS	Median	All	0.896	0.640	.013	4	view →
HNSC	DFS	Quartile	III,IV	0.270	1.000	.036	4	view →
LSCC	DFS	Median	All	0.885	0.524	.042	2	view →
PDAC	DFS	Quartile	All	0.296	0.535	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MT-ATP8 tumor-vs-normal RNA expression · all MT-ATP8 data types